论文部分内容阅读
目的评价阿托伐他汀对于缺血性脑血管病治疗的二级预防和干预效果。方法 100例缺血性脑血管病患者,随机分为甲组和乙组,各50例。甲组给予阿托伐他汀进行治疗,乙组给予辛伐他汀进行治疗。对比两组患者治疗后的不良反应发生情况及复发次数。结果甲组不良反应发生率4%低于乙组16%,差异具有统计学意义(χ2=4.0000,P<0.05)。随访1年,甲组的复发次数为(0.82±0.26)次,少于乙组的(1.47±0.52)次,差异具有统计学意义(t=7.9057,P<0.05)。结论阿托伐他汀对于缺血性脑血管病治疗的二级预防和干预效果显著,值得在临床应用推广和使用。
Objective To evaluate the secondary prevention and intervention effect of atorvastatin on ischemic cerebrovascular disease. Methods 100 cases of ischemic cerebrovascular disease were randomly divided into group A and group B, 50 cases each. Group A was treated with atorvastatin, Group B was treated with simvastatin. The incidence of adverse reactions and the number of relapse after treatment in both groups were compared. Results The incidence of adverse reactions in group A was 4% lower than that in group B (χ2 = 4.0000, P <0.05). One year follow-up, the recurrence frequency of group A was (0.82 ± 0.26) times, less than that of group B (1.47 ± 0.52). The difference was statistically significant (t = 7.9057, P <0.05). Conclusions Atorvastatin is effective in secondary prevention and intervention of ischemic cerebrovascular disease. It is worth to be popularized and used in clinical application.